MTOR and melanoma: That these include components of the Akt/mTOR signaling pathway (Akt S437, TOR S2448, PRAS40 T246) is not surprising since riluzole has been shown to inhibit Akt phosphorylation and synergize with mTOR inhibition in melanoma and glioblastoma models [26, 57].